United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - meropenem trihydrate - powder for solution for injection - 1gram

Ireland - English - HPRA (Health Products Regulatory Authority)

aurobindo pharma (malta) limited - meropenem - powder for solution for injection/infusion - 500 milligram(s) - carbapenems; meropenem

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

milpharm ltd - meropenem trihydrate - powder for solution for injection - 500mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

bowmed ibisqus ltd - meropenem trihydrate - powder for solution for injection - 1gram

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

fresenius kabi deutschland gmbh, germany - meropenem - powder for solution for injection/infusion - 500 mg

Canada - English - Health Canada

jamp pharma corporation - meropenem (meropenem trihydrate) - powder for solution - 500mg - meropenem (meropenem trihydrate) 500mg

Israel - English - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - meropenem as trihydrate - powder for solution for inj/inf - meropenem as trihydrate 500 mg/vial - meropenem - meropenem - meropenem is indicated for treatment in adults and children of the following severe infections caused by single or multiple susceptible bacteria sensitive to meropenem: - pneumonias and nosocomial pneumonias. - pulmonary infections in patients with cystic fibrosis. - urinary tract infections. - intra-abdominal infections. - gynecological infections such as endometritis and pelvic inflammatory disease. - skin and skin structure infections. - meningitis -septicemia. meropenem has proved efficacious alone or in combination with other antimicrobial agents in the treatment of polymicrobial infections. there is no experience in pediatric patients with neutropenia or primary or secondary immunodeficiency

Israel - English - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - meropenem as trihydrate - powder for solution for inj/inf - meropenem as trihydrate 1000 mg/vial - meropenem - meropenem - meropenem is indicated for treatment in adults and children of the following severe infections caused by single or multiple susceptible bacteria sensitive to meropenem: - pneumonias and nosocomial pneumonias. - pulmonary infections in patients with cystic fibrosis. - urinary tract infections. - intra-abdominal infections. - gynecological infections such as endometritis and pelvic inflammatory disease. - skin and skin structure infections. - meningitis -septicemia. meropenem has proved efficacious alone or in combination with other antimicrobial agents in the treatment of polymicrobial infections. there is no experience in pediatric patients with neutropenia or primary or secondary immunodeficiency

Canada - English - Health Canada

sun pharma canada inc - meropenem (meropenem trihydrate) - powder for solution - 500mg - meropenem (meropenem trihydrate) 500mg - carbapenems

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - meropenem trihydrate 570.475mg equivalent to meropenem 500 mg - powder for injection - 500 mg - active: meropenem trihydrate 570.475mg equivalent to meropenem 500 mg excipient: nitrogen sodium carbonate - dbl meropenem for injection is indicated for treatment of the following infections, in adults and children (aged 3 months and over), when the causative organisms are known or suspected to be resistant to commonly used antibiotics: · community acquired lower respiratory tract infection · hospital acquired lower respiratory tract infection · complicated urinary tract infection · febrile neutropenia · intra-abdominal and gynaecological (polymicrobial) infections · complicated skin and skin structure infections · meningitis · septicaemia